Literature DB >> 26476226

Comorbidities in Psoriatic Arthritis.

M Elaine Husni1.   

Abstract

Epidemiologic studies have shown that, in patients with psoriatic arthritis (PsA), associated comorbidities may occur more frequently than expected. This article discusses related comorbidities in patients with PsA. Identifying these comorbidities may affect the management and treatment decisions for these patients to ensure an optimal clinical outcome. All health care providers caring for patients with PsA should be aware of the relevant comorbidities and should have an understanding of how these comorbidities affect management. The common comorbidities include cardiovascular disease, metabolic syndrome, obesity, diabetes, fatty liver disease, inflammatory bowel disease, ophthalmic disease, kidney disease, osteoporosis, depression, and anxiety.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Comorbidity; Management; Psoriasis; Psoriatic arthritis; Screening

Mesh:

Year:  2015        PMID: 26476226     DOI: 10.1016/j.rdc.2015.07.008

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  25 in total

Review 1.  Multidisciplinary Management of Psoriatic Arthritis: The Benefits of a Comprehensive Approach.

Authors:  Elisa Visalli; Natascia Crispino; Rosario Foti
Journal:  Adv Ther       Date:  2019-02-25       Impact factor: 3.845

2.  Addressing comorbidities in psoriatic disease.

Authors:  Priya Patel; Cheryl F Rosen; Vinod Chandran; Yang Justine Ye; Dafna D Gladman
Journal:  Rheumatol Int       Date:  2017-11-28       Impact factor: 2.631

3.  Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.

Authors:  Ennio G Favalli; Andrea Becciolini; Antonio Carletto; Fabrizio Conti; Giorgio Amato; Enrico Fusaro; Luca Quartuccio; Colin Gerard Egan; Andrea Lo Monaco; Maurizio Benucci; Fausto Salaffi; Angelo Semeraro; Simone Parisi; Fulvia Ceccarelli; Ilaria Piazza; Rosario Foti
Journal:  Rheumatol Int       Date:  2019-08-21       Impact factor: 2.631

4.  Assessment of Periodontal status in Patients with Psoriatic Arthritis: A retrospective, case-control study.

Authors:  Supriya Mishra; Lynn Johnson; Sangita Agrawal; Shikha Rajput
Journal:  J Clin Exp Dent       Date:  2021-08-01

5.  Current Medication Practices and Preferences Among Patients With Psoriatic Arthritis.

Authors:  Monica Schwartzman; Zafir Abutalib; Lisa A Mandl
Journal:  J Clin Rheumatol       Date:  2022-03-01       Impact factor: 3.902

Review 6.  Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review.

Authors:  Elena Nikiphorou; George E Fragoulis
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-06-27       Impact factor: 5.346

7.  Prevalence and type II diabetes-associated factors in psoriatic arthritis.

Authors:  Rubén Queiro; Andrés Lorenzo; Estefanía Pardo; Anahy Brandy; Pablo Coto; Javier Ballina
Journal:  Clin Rheumatol       Date:  2018-02-22       Impact factor: 2.980

8.  Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study.

Authors:  Nadeem Ahmed; James A Prior; Ying Chen; Richard Hayward; Christian D Mallen; Samantha L Hider
Journal:  Clin Rheumatol       Date:  2016-08-02       Impact factor: 2.980

Review 9.  Comorbidities in Patients with Psoriatic Arthritis.

Authors:  Amir Haddad; Devy Zisman
Journal:  Rambam Maimonides Med J       Date:  2017-01-30

10.  Management of Psoriatic Arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions.

Authors:  Kemal Nas; Erkan Kiliç; Remzi Çevik; Hatice Bodur; Şebnem Ataman; Figen Ayhan; Özgür Akgül; Ayşen Akinci; Zuhal Altay; Erhan Çapkın; Abdullah Zübeyir Dağli; Tuncay Duruöz; Gülcan Gürer; Feride Göğüş; Yeşim Garip; Cahit Kaçar; Ayhan Kamanli; Ece Kaptanoğlu; Taciser Kaya; Hilal Kocabaş; Erhan Ali Özdemirel; Sumru Özel; İlhan Sezer; İsmihan Sunar; Gürkan Yilmaz
Journal:  Arch Rheumatol       Date:  2018-05-21       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.